A previous study of KP372-1 on acute myelognous leukemia (AML) suggests that this drug predominantly acts on inhibition of PDK1/Akt-mediated anti-apoptosis mechanism but has no function on arresting cell cycle progression[59]. This evidence concerns the gene AKT1 and acute myeloid leukemia.